Diagnosing Staph Infections: Cultures, Sensitivity Testing, and MRSA Identification

Table of Contents

  1. Why Accurate Diagnosis Matters
  2. Blood Culture Technique
  3. Wound Cultures vs. Surface Swabs
  4. Nasal Swab Screening for MRSA Carriage
  5. Antibiogram and Minimum Inhibitory Concentration
  6. Oxacillin Resistance Testing and mecA
  7. Chromogenic Agar for Rapid MRSA Detection
  8. Echocardiography in Staph Bacteremia
  9. When to Repeat Blood Cultures
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Why Accurate Diagnosis Matters

When a doctor suspects a staph infection, the temptation is to start antibiotics immediately and sort out the details later. That instinct is right for life-threatening presentations — but the choice of antibiotic matters enormously, and getting it wrong can have serious consequences.

The core problem is that Staphylococcus aureus comes in two main flavors: regular staph (MSSA — methicillin-susceptible) and MRSA (methicillin-resistant). MSSA is easily killed by common penicillin-family antibiotics like nafcillin or oxacillin. MRSA laughs at those drugs. If a patient has MRSA and receives nafcillin, the bacteria keep multiplying while the treatment window narrows. The infection spreads, complications worsen, and the patient may become critically ill before anyone realizes the antibiotic is useless.

On the flip side, treating every suspected staph infection with vancomycin — the main MRSA drug — has its own costs. Vancomycin is harder on the kidneys, more difficult to dose correctly, and its overuse accelerates resistance. When lab results confirm MSSA, the right move is to step down to nafcillin or cefazolin, which actually work better against MSSA than vancomycin does.

This is why cultures and sensitivity testing are not just box-checking exercises. They are the information foundation on which safe, effective antibiotic decisions are made. Every hour of delay in identifying the organism and its resistance profile is an hour of suboptimal treatment.

Blood Culture Technique

Blood cultures are the most important test in suspected staph bacteremia (staph in the bloodstream). The goal is to capture live bacteria circulating in the blood and grow them in the lab so they can be identified and tested against antibiotics.

The two-set rule. Standard practice is to collect two sets of blood cultures from two separate venipuncture sites — meaning two different spots on the body, not two draws from the same IV line. Each set consists of two bottles: one aerobic (oxygen-present) and one anaerobic (oxygen-free). The reason for two sites is contamination control. Skin bacteria sometimes get into the bottle accidentally during the draw. If only one site grows bacteria, it may be a contaminant. If both sites grow the same organism, you have real bacteremia.

Volume matters. Each bottle should receive approximately 10 mL of blood. This sounds like a lot, but blood cultures fail to detect bacteria when too little blood is submitted. Studies consistently show that 20–30 mL total per draw event significantly improves detection rates compared to smaller volumes. In critically ill patients where bacteremia is strongly suspected, up to three sets may be collected.

Timing relative to antibiotics. Ideally, blood cultures are collected before the first antibiotic dose. Even one dose of antibiotics can reduce the bacterial load enough to push a culture negative, leaving clinicians without a confirmed diagnosis. In practice, if someone is septic, treatment should not be delayed more than 45 minutes waiting for cultures — but the cultures should go in first whenever possible.

What happens in the lab. Bottles are loaded into automated incubation systems that continuously monitor for bacterial growth by detecting carbon dioxide production. Most positive blood cultures flag within 12 to 48 hours. S. aureus is a relatively fast grower — positives often flag within 12 to 24 hours. Once flagged positive, the lab performs a Gram stain immediately: a Gram-positive coccus in clusters is a strong early indicator of S. aureus, triggering rapid MRSA testing even before formal identification is complete.

Wound Cultures vs. Surface Swabs

Not every staph infection involves the bloodstream. Skin abscesses, infected surgical wounds, diabetic foot ulcers, and pressure injuries are common presentations where clinicians need to identify the organism and its antibiotic sensitivities.

The contamination problem with surface swabs. Swabbing the visible surface of an open wound is convenient but often misleading. Every open wound — even a clean one — is colonized by skin bacteria. Running a swab across the surface picks up whatever is living on top, which may include several species that have nothing to do with the actual infection. The result is a culture report listing multiple organisms, most of which are colonizers, not pathogens. Deciding which one to treat becomes a guessing game.

Better specimens: aspirated pus and tissue. The most reliable wound culture specimens are aspirated pus from an abscess (collected by needle before incision, or during incision and drainage), or a tissue biopsy from the wound margin. These samples come from inside the infected tissue where contaminating surface bacteria have not reached. The result reflects what is actually causing the infection.

For a diabetic foot wound or pressure ulcer, the preferred approach is debridement of the wound surface (removing the top layer of slough and colonized tissue) followed by a curettage sample or punch biopsy of the wound base. This is more work than a swab but dramatically increases the clinical value of the result.

When surface swabs are appropriate. For screening purposes — such as checking whether a patient's wound is colonized with MRSA before a procedure — a swab is acceptable because the question being asked is colonization, not infection. The distinction between colonization and infection is critical: colonization means bacteria are present but not causing tissue damage or systemic illness; infection means they are.

Nasal Swab Screening for MRSA Carriage

Roughly 30% of the general population carries S. aureus in their nostrils without any symptoms or illness. About 1–3% of the population carries MRSA specifically. This carriage state matters in two ways: carriers are at higher risk of self-infection (their own nasal bacteria can seed surgical sites, IV lines, or wounds), and carriers can spread MRSA to vulnerable patients in hospital settings.

How the swab is collected. Nasal MRSA screening uses a swab inserted about 1–2 cm into each anterior naris (nostril opening), rotated several times against the mucosa to pick up cells and any bacteria present. It is quick and painless. The swab is then sent to the lab for one of two methods.

PCR vs. chromogenic agar for screening. PCR-based nasal screens detect the mecA or mecC gene directly from the swab within 1–2 hours. This is highly accurate and fast, but more expensive. Chromogenic agar cultures take 18–48 hours but are cheaper and can be done in standard labs without specialized PCR equipment. Many hospitals use PCR for pre-operative screening where a same-day result changes the surgical plan, and agar-based methods for routine admission screening where a next-day result is acceptable.

What a positive nasal screen means. A positive nasal screen means the person is a carrier — not that they have an active infection. Carriers are often offered decolonization treatment (mupirocin ointment in the nose, chlorhexidine body washes) before elective surgery to reduce the risk of a post-operative staph infection. A positive screen before cardiac or orthopedic surgery, in particular, triggers a decolonization protocol because infections involving heart valves or prosthetic joints are catastrophic.

Patients sometimes become alarmed when told they are MRSA carriers. It is important to explain that carriage is common and does not mean they are sick or infectious to healthy people in normal daily life — it is mainly a risk factor in healthcare settings involving invasive procedures.

Antibiogram and Minimum Inhibitory Concentration

Once a lab grows S. aureus from a culture, the next question is: which antibiotics can actually kill this particular strain? The answer comes from susceptibility testing, which produces two tools: the antibiogram and the minimum inhibitory concentration (MIC).

Disk diffusion (Kirby-Bauer). The most widely used susceptibility testing method is disk diffusion. The lab spreads the isolated bacteria evenly across an agar plate, then places small paper disks impregnated with different antibiotics on the surface. The plate incubates overnight. Each antibiotic diffuses outward through the agar, killing bacteria in a zone around the disk. A large clear zone means the bacteria are susceptible — the antibiotic kills them. A small or absent zone means resistance.

The lab measures each zone diameter in millimeters and compares it to published breakpoints from the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Each antibiotic gets reported as Susceptible (S), Intermediate (I), or Resistant (R).

Minimum inhibitory concentration. MIC testing goes further than disk diffusion by measuring the lowest concentration of an antibiotic that visibly stops bacterial growth. The result is expressed in micrograms per milliliter (mcg/mL). A vancomycin MIC of 0.5 mcg/mL means vancomycin stops growth at a low concentration — the bacteria are highly susceptible. A MIC of 2 mcg/mL is at the upper boundary of susceptibility. Anything above 2 mcg/mL is resistant.

Why vancomycin MIC matters. For MRSA infections, vancomycin is often the treatment backbone. But clinical outcomes worsen when the vancomycin MIC for a patient's MRSA strain is 2 mcg/mL versus 0.5 mcg/mL — even when both strains are technically "susceptible." Strains with higher MICs are harder to clear, especially in serious infections like bacteremia or endocarditis. Knowing the MIC helps the infectious disease team decide whether to continue vancomycin, target a higher drug concentration, or switch to an alternative like daptomycin or ceftaroline.

Oxacillin Resistance Testing and mecA

Identifying MRSA specifically — not just any antibiotic-resistant staph — requires testing for resistance to the methicillin/oxacillin class of beta-lactam antibiotics. This is the defining characteristic of MRSA, and it is detected by several overlapping methods.

Cefoxitin disk diffusion. Paradoxically, MRSA is best detected by disk diffusion using cefoxitin, not oxacillin. Cefoxitin is a more reliable inducer of resistance expression: MRSA strains that might give borderline results with an oxacillin disk give clear, unambiguous resistance with cefoxitin. A zone diameter of 21 mm or less with the cefoxitin disk predicts mecA-mediated MRSA. This is now the standard initial screen in most clinical labs.

mecA PCR: the gold standard. The mecA gene encodes PBP2a (penicillin-binding protein 2a), the altered cell-wall building protein that makes MRSA resistant to virtually all beta-lactams. PCR directly detects the presence of the mecA gene in bacterial DNA, regardless of how the organism behaves on culture. If mecA is present, the strain is MRSA, period — even if disk diffusion gives an ambiguous result. A related gene, mecC, is less common but confers the same resistance; PCR assays should detect both.

MALDI-TOF for rapid identification. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) has transformed clinical microbiology by identifying organisms in minutes from a colony, based on protein fingerprinting. While standard MALDI-TOF identifies the species (S. aureus vs. coagulase-negative staph), newer algorithms can distinguish MRSA from MSSA without separate mecA testing, though this capability is not yet universal across all laboratory platforms.

Together, cefoxitin disk diffusion plus mecA PCR (when needed) gives a highly accurate and rapid MRSA call — typically achievable within 24–48 hours of the initial positive blood culture flag.

Chromogenic Agar for Rapid MRSA Detection

Chromogenic agar is a specialized culture medium used primarily for MRSA screening — particularly from nasal swabs, wound surfaces, and environmental samples in high-risk hospital units. It offers a fast, visual result without requiring separate molecular testing.

How the color reaction works. Chromogenic agar contains substrates that bacterial enzymes cleave to release colored compounds. MRSA produces specific enzyme combinations that generate a distinctive color — typically pink to mauve — when grown on these plates. Other bacteria either fail to grow (because the medium contains inhibitors against Gram-negative organisms and common skin flora) or grow in a different color.

A technician reading the plate can often identify suspect MRSA colonies visually without additional testing steps. Confirmation with mecA PCR or disk diffusion is still performed, but the color reaction provides rapid triage information.

Speed advantage. Standard culture on blood agar requires 48–72 hours of incubation before colonies are large enough to test. Chromogenic agar produces readable results in 18–24 hours for most strains. For hospitals doing pre-operative MRSA screening, this speed can allow decolonization to begin the day before surgery rather than the week before — or can provide a same-day result for patients being admitted urgently.

Where chromogenic agar is used. Intensive care units, cardiac surgery wards, and transplant units frequently screen all new admissions for MRSA using chromogenic agar to identify carriers before they can spread the organism to other patients. The UK and several European countries have implemented universal admission MRSA screening in high-risk NHS wards. In the US, screening is more targeted to high-risk patient groups (prior MRSA history, dialysis patients, recent hospitalization).

Echocardiography in Staph Bacteremia

When blood cultures confirm S. aureus bacteremia, one of the most critical questions is: has the infection seeded the heart valves? Staphylococcal endocarditis — infection of the heart valves — is a life-threatening complication that changes treatment duration from 2 weeks to 6 weeks, may require cardiac surgery, and has a mortality rate of 20–40% even with treatment.

The problem is that early endocarditis can be clinically silent. A patient may have no heart murmur, no embolic signs, and no symptoms pointing to the heart. Without imaging, endocarditis is missed until the vegetations (bacterial masses on the valve) grow large enough to cause valve destruction, embolic strokes, or abscess formation in the heart muscle.

Transthoracic vs. transesophageal echocardiography. Transthoracic echocardiography (TTE) uses an ultrasound probe on the chest wall. It is non-invasive and widely available, but image quality depends on body habitus — in obese patients, patients with emphysema, or patients on mechanical ventilation, the lung and chest wall block the acoustic window and TTE images are often inadequate.

Transesophageal echocardiography (TEE) passes the ultrasound probe down the esophagus, which sits directly behind the heart. This provides dramatically better images of the heart valves — particularly the mitral valve and aortic valve — and can detect vegetations as small as 2–3 mm that TTE would miss completely.

When TEE is mandatory. Current guidelines recommend TEE (not just TTE) in S. aureus bacteremia when any of the following apply: prosthetic heart valve or cardiac device (pacemaker, defibrillator), persistent bacteremia after 72 hours of appropriate antibiotics, poor TTE image quality, clinical signs suggesting embolism or metastatic infection, or any patient where the duration of therapy depends on whether endocarditis is present. Many infectious disease specialists advocate TEE for essentially all cases of S. aureus bacteremia, given how frequently endocarditis is found and how serious the consequences of missing it are.

What a vegetation looks like. On echocardiography, a vegetation appears as an irregular, oscillating mass attached to a valve leaflet. It moves chaotically with the cardiac cycle, independent of the valve movement. Vegetations on the aortic or mitral valve (left-sided endocarditis) embolize to the brain, spleen, and kidneys. Right-sided vegetations (tricuspid valve, common in injection drug users) embolize to the lungs, causing septic pulmonary emboli.

When to Repeat Blood Cultures

The work of blood culture is not finished when the initial positive result confirms S. aureus bacteremia. Serial cultures — repeated draws over the course of treatment — are essential for managing the infection safely.

48–72-hour clearance cultures. Standard practice in S. aureus bacteremia is to repeat blood cultures 48–72 hours after starting appropriate antibiotics. The goal is to confirm that the bacteremia has cleared — that the blood is now sterile. If cultures at 48–72 hours remain positive, this is a major red flag indicating either inadequate antibiotic therapy, an undrained source of infection (abscess, infected device), or occult endocarditis seeding the blood continuously.

Persistent bacteremia: what it means. Persistent bacteremia (positive cultures for more than 3–4 days despite appropriate antibiotics) demands aggressive investigation. The most likely explanations are an infected intravascular device (central venous catheter, pacemaker lead) that must be removed, an undrained abscess or septic joint that must be surgically drained, or infective endocarditis with continuous seeding from a valve vegetation. Each of these requires a specific intervention beyond antibiotics alone.

Why clearance time determines treatment duration. The number of days from the first positive blood culture to the first confirmed negative culture — called the duration of bacteremia — directly shapes antibiotic treatment duration. For uncomplicated S. aureus bacteremia (source removed, no endocarditis, negative TEE, rapid clearance), a minimum of 14 days of intravenous antibiotics is standard. For complicated bacteremia (endocarditis, vertebral osteomyelitis, persistent positive cultures), the duration extends to 4–6 weeks. Missing or delaying repeat cultures means missing the information needed to make this calculation correctly.

Negative cultures do not mean cure. Clearance of bacteremia is a necessary milestone, not a finish line. Bacteria can seed deep tissues — bone, vertebral discs, kidneys, spleen — during the bacteremic phase and establish infections that continue smoldering after blood cultures turn negative. This is why follow-up imaging (MRI of the spine in prolonged bacteremia, CT of the abdomen in persistent fever) is often performed alongside repeat cultures.

Key Research Papers

The following studies underpin current diagnostic practices in S. aureus infection and MRSA identification.

  1. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003;163(17):2066–2072. PMID: 14504120
  2. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633–638. PMID: 10770721
  3. Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications. Circulation. 2015;132(15):1435–1486. PMID: 26293308
  4. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1–45. PMID: 19494366
  5. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53–59. PMID: 12384842
  6. Lodise TP Jr, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003;36(11):1418–1423. PMID: 12766839
  7. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666–674. PMID: 16301024
  8. Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis. 2009;48 Suppl 4:S231–237. PMID: 19374579
  9. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339(8):520–532. PMID: 9709046
  10. Holland TL, Arnold C, Fowler VG Jr. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA. 2014;312(13):1330–1341. PMID: 25268440
  11. Safdar N, Fine JP, Maki DG. Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection. Ann Intern Med. 2005;142(6):451–466. PMID: 15541481
  12. Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5(12):751–762. PMID: 16301024
  13. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23(3):616–687. PMID: 21208910

Connections

Back to Table of Contents